

# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ | ABL

Q4 2023

#### Disclaimer

General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment. None of Abacus Life, Inc. (the "Company") or its affiliates has authorized anyone to provide interested parties with additional or different information. No securities regulatory authority has expressed an opinion about the securities discussed in this Presentation and it is an offense to claim otherwise. The information contained herein does not purport to be all inclusive or contain all of the information that may be required to make a full analysis of the Company. Viewers of this Presentation should each make their own evaluation of the Company and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice, and you should consult with your own attorney, business advisor and tax advisor as to legal, business, tax and other matters related hereto. No representatives, partners, directors, officers, employees, advisers or agents (collectively, the "Representatives") be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith.

**Forward-Looking Information**. This Presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the Company, including statements regarding the future financial condition and performance of the Company and the platform and markets and expected future growth and market opportunities of the Company. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "scales," "representative of," "valuation," "potential," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions or the negatives of these terms or variations of them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and, as a result, are inherently subject to risks and uncertainties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond the Company's control, are difficult or impossible to predict and may differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this Presentation.

Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should carefully consider the foregoing factors and the other risks and uncertainties which will be more fully described in the "Risk Factors" section of the Company's SEC filings made from time to time with the Securities and Exchange Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Viewers of this Presentation are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements , whether as a result of new information, future events, or otherwise. The Company does not give any assurance that the Company will achieve expectations.

No Offer or Solicitation. This Presentation is for informational purposes only and shall not constitute an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended, or otherwise in accordance with applicable law.

Use of Projections. This Presentation contains financial forecasts with respect to the Company's projected revenue, net income and return on equity for 2023. The financial and operation forecasts and projections contained herein represent certain estimates of the Company as of the date hereof and are included herein for illustrative purposes only. The Company's independent public accountants have not audited, examined, reviewed, compiled or performed any procedures with respect to the forecasts or projections and, accordingly, do not express an opinion or other form of assurance with respect thereto. These projections should not be relied upon as being necessarily indicative of future results. In this Presentation, certain of the above mentioned projected information has been repeated (in each case, with an indication that the information is an estimate and is subject to the qualifications presented herein) for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic, regulatory and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contai

**Financial Information**; Some of the financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X. Such information and data may not be included in, may be adjusted in or may be presented differently in the proxy statement to be filed relating to the Transaction. Except as otherwise noted, all references herein to full-year periods refer to the Abacus Companies' fiscal year, which ends on December 31. You should review the Abacus Companies' audited financial statements, which will be included in the proxy statement to be filed in connection with the Transaction.

Industry And Market Data. This Presentation has been prepared by the Company and includes market data and other statistical information from third party sources are reliable as of their respective dates, none of the Company or any of its respective Representatives has independently verified the accuracy or completeness of this information and cannot guarantee its accuracy and completeness. Some data is also based on good faith estimates of the Company, which are derived from both internal sources and the third party sources described above. None of the Company or its respective Representatives make any representation or warranty with respect to the accuracy of such information.





Growth Company in an Essentially Uncorrelated Alternative Asset Class with a Large TAM, Institutional Investment Grade Counterparties



Abacus is a leading alternative investment originator and asset manager



19 consecutive years of positive net income



Proprietary Longevity Technology Platform



Original Management Team and Founders



#### Overview of Abacus Life (ABL)

	ife Insurance Acquisition		<b>Private Wealth</b>		Data & Technology
Ť	Business Description		Business Description	<b>I</b>	Business Description
Abacus Settlements, LLC	fully integrated Advisor, Agent and consumer facing secondary market origination platform	Abacus Life Advisors	fully integrated consumer facing RIA & Broker Dealer	Abacus Life Technologies	Lifespan data AI platform developing full stack programs to build, predict and value lifespan based products
		Abacus Lifespan Funds	Model ETF Strategy that utilizes individual lifespan to determine asset allocation		
Longevity Market Assets, LLC	Actively managed originations held for investment and serviced with support from valuation and due diligence team	Abacus Equity Income Fund	1940 Act Interval Mutual Fund with daily valuation and quarterly liquidity	Life and Mortality Tracker	Lifetrac and Mortality tracking services for asset managers, pension funds, unions, government agencies



#### Abacus Life – ABL Board




**ABACUS LIFE** OPTIONS FOR YOUR LIFE INSURANCE NASDAQ | ABL



**Jay Jackson** 

Chairman

Abacus Life CEO with 25+ years longevity asset experience Built multiple origination & platform providers in longevity asset management and technology.



**ABACUS LIFE** OPTIONS FOR YOUR LIFE INSURANCE





Sean McNealv

Director

Abacus Life Co-Founder 25+ years in policy origination experience Established over 30K relationships with Financials Advisors and Insurance Agents Rand Capital Board of Director







Director

12+ years as CIO for East Management Services Responsible for financial & business due diligence of all acquisitions









Karla Radka

Director

President & CEO of Senior Resource Alliance 25+ years of experience in business development, nonprofit management, health and social issues, and community impact.









Thomas W. Corbett Jr.

#### Director

Principal member of Corbett *Consulting*, *LLC since 2015* Former Governor of Pennsylvania Former PA Attorney General

and US Attorney for the Western District of PA









Former CFO, Treasurer, Director & EVP at Transamerica Life Insurance Co. (Iowa) and Treasurer & Senior Vice President at Transamerica Advisors Life Insurance Company of NY






**Beth Schulte, CPA, MBA** 

Director

CFO of Attivo Partners *30+years of accounting and* CFO experience working for Big 4 accounting firms including EY and KPMG






# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ | ABL

Life Insurance Acquisition & Management

### Overview of Abacus Life – Life Insurance Acquisition

We have built a leading vertically integrated alternative asset manager specializing in life insurance products






1. Includes policies originated, owned, and / or serviced by Abacus through June 2023

7

#### Large Total Addressable Market with Meaningful Growth Potential




We believe that we provide an attractive solution for life insurance policyholders to monetize an underutilized asset





Sources: Life Insurance Industry per the American Council of Life Insurers Annual Report (2020). American Real Estate Industry per the MSCI – Real Estate Market Size report (2021 / 2022). Percent of insurance policies that do not pay claims per the Life Settlement Insights (Observations and Commentary on the Life Settlement Market) report. Annual Life Settlement Market Opportunity per Strategic Study Series Insurance Research, Life Settlements "A Market Takes Off" (2019) provided by Conning, Inc. Annual Life Settlement Market Rankings (2021). Percentages of awareness and willingness for life settlement per Life Insurance Settlement Association (annual survey of insureds who let the policy lapse). Percent of advisors and agents that transact based on number of estimated financial advisors per Occupational Employment and Wage Statistics data provided by the U.S. Bureau of Labor Statistics, Abacus' market share and observed success rate with financial advisors. 1. Total Life Insurance Industry refers to total face value of individual life insurance policies in force in 2020. Annual Life Settlement Market Opportunity includes policies with estimated age of policy holder over 65 years old. Current Annual Life Settlement Market Terres to total face value of policies settled in 2021.

#### Uncorrelated Alternative Asset with Institutional Investment Grade Counterparts



Source: Policy Cash Value Over Time chart based on a \$1 million death benefit, ~3% cash value rate of increase, beginning at 35-years old and paying out at 100-years old. A-cyclical and essentially uncorrelated returns based on the average return and associated standard deviation chart – based on 3-year comparative return for a variety of market indices per Yahoo Finance.

1. A Rating or better determined by AM Best and classified as insurance companies that have or exceed an "excellent ability to meet their ongoing obligations".


Age of Policy Holder

ABACUS LIFE

2. Abacus return and standard deviation based on its entire portfolio (holding and trading) as of August 2022 and then extrapolated to August 2025, assuming zero mortalities.

**Standard Deviation** 


#### Abacus is at the Heart of the Life Settlements Industry





Source: Market share data per The Deal and based on number of settlements provided from 2017 – 2022. Note: All portfolio trading performance metrics measured from 2019 through 2023.

#### **ORIGINATION MACHINE with a Model to Drive Economics**



Diversification Across Multiple Origination Channels Creates a Lower Average Policy Acquisition Cost

long-term relationships with 78 institutional origination partners


access to over 30,000 financial advisors


70-person origination team with 30 sales members, assigned by channel

49 states with ability / license to operate




#### 2024 Operations & Execution Team










# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ | ABL

ABL Wealth


#### Aggregated Historical Track Record





1. Construct policy tranches for a range of institutional buyers 1-2-day trading process given policies are held at securities intermediary and the securities of the securi

#### ABL Longevity Growth and Income Fund Target Launch 2024 – ABLGX(1)





This slide is for illustrative purposes only. The launch, operation and success of the Fund is subject to significant risks and uncertainties, including SEC approval, Company's ability to manage the Fund, the ability to attract investors, ability to acquire and manage Fund assets and the ability to achieve the illustrative yield, growth and total return. Primary Custodian is Wilmington Trust and UMB




Offer custom financial solutions using Lifespan as the core driver of portfolio allocation

Acquire strategic RIAs and Advisors








# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ ABL

The Power of Data & Tech: ABL Technologies (abltech.com)

### ABL Tech – Mortality Tracking





### ABL Tech: Aging IQ and Live Life Table

#### Drive Wealth Planning Through AI & Longevity



#### MyTrueAge

• AI Technology to estimate biological age

#### MyLifeScore


• Data-Driven approach to estimating healthspan and lifespan






### Live Life Table







### Proprietary Technology Platform Yields Differentiated Underwriting Capabilities



#### **Instant Policy Valuations**

Policy Value Calculator <sup>1</sup>		
Health Status	Average Pr	
Standard	\$42,890	
Slightly Impaired	\$95,980	
Moderately Impaired	\$129,150	
Highly Impaired	\$203,410	
Extremely Impaired	\$256,790	
Terminal Illness	Up to \$800,00	
CLE	AR	
	Health Status Standard Slightly Impaired Moderately Impaired Highly Impaired Extremely Impaired Terminal Illness	




20


**Average Price** 

Up to \$800,000

#### ABL Tech: Abacus Marketplace and Blockchain Integration







# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ ABL

Marketing and Advertising


### Marketing Performance/Strategy



- National strategy continues to perform well, generating a 13x lead growth YoY
- 67,618 seniors spoke to Abacus about their policies


- Market saturation is strong on major news channels including Fox, CNN, FBN, Bloomberg, and MSNBC
- Diminishing returns not yet reached, CPL continues to drop with higher spend volume
- Low competition; high intent leads






# ABACUS LIFE KNOW THE VALUE OF YOUR LIFE NASDAQ ABL


Q4 Financial Information and Proforma





### 10-Q 4th Quarter Financial Summary





#### FY 2023 Financials Overview

Gross Revenue	\$79.4 million
EBITDA	\$39.3 million
Origination Capital Deployed	\$219 million



#### FY 2023 Financial Information Abacus Life, Inc. Proforma Revenue and Operating Expenses

	FY 2023	FY 2022
Revenues:		
Portfolio Servicing	1,002,174	1,470,972
Origination	10,596,541	25,203,463
Active Management	67,990,018	43,242,580
Total Revenue	79,588,733	69,917,015
Operating Expenses:		
Sales and marketing	4,905,747	2,596,140
General, administrative and other	31,331,151	9,971,247
(Gain) loss on change in fair value of debt	2,356,058	90,719
Unrealized loss (gain) on investments	(1,369,111)	1,045,623
Depreciation and amortization expense	3,415,525	18,588
Total Operating Expenses	40,639,370	13,722,317



	FY 2023	FY 2022
Net Income attributable to Abacus Life, Inc.	\$ 9,516,628	\$31,682,276
Net Income for Abacus Settlements, LLC [1]	(974,901)	(52,495)
Net income attributable to Abacus Life, Inc.	8,541,727	31,629,781
Net income attributable to non-controlling interests	(482,139)	704,699
Amortization of intangibles	3,364,167	-
Stock compensation expense	10,768,024	-
Loss on change in fair value of warrant liability	4,204,360	-
Tax impact [2]	2,069,993	
Proforma Adjusted Net Income	\$ 28,466,132	\$ 32,334,480

[1] Net income attributable to Abacus Settlements, LLC in 2023 includes YTD June 2023 and all of 2022

[2] Tax impact represents the permanent difference in tax expense related to the restricted stock awards granted to certain executives due to IRC 162(m) limitations.



#### FY 2023 Financial Information (cont'd) Abacus Life, Inc. Proforma Adjusted EBITDA

	FY 2023	FY 2022
Net Income attributable to Abacus Life, Inc.	\$ 9,034,489	\$ 32,386,975
Net Income for Abacus Settlements, LLC	(974,901)	(52,495)
Proforma Net Income	8,059,588	32,334,480
Depreciation and amortization expense	3,481,174	109,604
Interest expense	9,866,657	51,615
Interest income	(596,681)	(3,673)
Income tax	1,471,721	891,961
Stock compensation	10,768,024	-
Other (Income) / Expense	(108,200)	346,740
Loss on change in fair value of warrant liability	4,204,360	-
Loss on change in fair value of debt	2,356,085	90,719
Unrealized (gain) / loss on investments	(1,369,112)	1,045,623
Proforma Adjusted EBITDA	\$ 38,133,589	\$34,867,069



	For the Year Ended
Return on Equity	December 31, 2023
Total Stockholder's Equity	164,070,076
Net Income Attributable to common stockholders	9,516,626
ROE	5.8%
Proforma Adjusted Net income	28,466,132
Adjusted ROE	17%

	For the Year Ended
Return on Invested Capital	December 31, 2023
Total Assets	331,826,067
Less:	
Intangible assets, net	(29,623,130)
Goodwill	(140,287,000)
Current Liabilities	(23,326,331)
Total Invested Capital	138,589,606
Net Income Attributable to common stockholders	9,516,626
ROIC	6.9%
Proforma Adjusted Net income	28,466,132
Adjusted ROIC	21%

\* Annualized return on invested capital (ROIC), a non-GAAP measure, is defined as Adjusted net income for the quarter divided by the result of Total Assets less Intangible assets, net, Goodwill and Current Liabilities multiplied by four. ROIC is not a measure of financial performance under GAAP. We believe ROIC should be considered in addition to, not as a substitute for, operating income or loss, net income or loss, cash flows provided by or used in operating, investing and financing activities or other income statement or cash flow statement line items reported in accordance with GAAP.

Annualized return on equity (ROE), a non-GAAP measure, is defined as Adjusted net income divided by total shareholder equity multiplied by four. ROE is not a measure of financial performance under GAAP. We believe ROE should be considered in addition to, not as a substitute for, operating income or loss, net income or loss, cash flows provided by or used in operating, investing and financing activities or other income statement or cash flow statement line items reported in accordance with GAAP.

Management uses ROE and ROIC as internal operating performance measures in the management of business as part of our capital allocation process. We believe ROE and ROIC provide useful supplemental information to investors as it is frequently used by the financial community to analyze financial performance between periods and for comparison among companies. ROE and ROIC should not be viewed as a substitute for metrics calculated in accordance with GAAP, and other companies may define these metrics differently.





#### Consolidated Proforma Historical Financial KPIs (Q1 2022 – Q4 2023)

(\$ in millions) \$23.7 \$21.1 \$21.1 \$17.5 \$18.3 \$17.2 \$16.6 \$14.1 Q3 2022 Q4 2022 Q1 2022 Q2 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023


Revenue

Adjusted Quarterly Return on Invested Capital







Adjusted Quarterly Return on Equity




### Additional Origination KPIs (Q1 2022 – Q4 2023)




#### Number of Originations



#### **Face Value Originated Through Abacus**







# **ABACUS LIFE**

### KNOW THE VALUE OF YOUR LIFE

### NASDAQ | ABL